Patient characteristics in the TL-pre-CAR-T set at the time of enrollment in the DESCAR-T registry
| . | TL-pre-CAR-T set . | |
|---|---|---|
| N = 15 . | ||
| Age (y) | ||
| Median (min; max) | 71.0 (47; 80) | |
| Age ≥65 y | 10 | (66.7%) |
| Sex, male | 10 | (66.7%) |
| ECOG | ||
| 0-1 | 13 | (86.7%) |
| >2 | 2 | (13.3%) |
| LDH > normal | ||
| No | 7 | (50.0%) |
| Yes | 7 | (50.0%) |
| Missing | 1 | |
| Ann Arbor stage | ||
| I-II | 2 | (15.4%) |
| III-IV | 11 | (84.6%) |
| Missing | 2 | |
| aaIPI | ||
| 1 | 7 | (58.3%) |
| 2 | 4 | (33.3%) |
| 3 | 1 | (8.3%) |
| Missing | 3 | |
| Histology | ||
| LBCL | 11 | (73.3%) |
| Transformed FL | 3 | (20.0%) |
| Transformed Hodgkin | 1 | (6.7%) |
| HCT-CI-comorbidity evaluated | 15 | (100.0%) |
| At least 1 HCT-CI-comorbidity | 7 | (46.7%) |
| Nb of PLT before CAR-T∗ | ||
| Median (min; max) | 3.0 (2; 7) | |
| Prior autologous transplant | 1 | (6.7%) |
| Time from the initial diagnosis to CAR T-cell eligibility (y) | ||
| Median (min; max) | 1.62 (0.5; 18.2) | |
| Disease status before leukapheresis | ||
| Refractory | 14 | (100.0%) |
| Missing | 1 | |
| Disease status before CAR T-cell infusion | ||
| CR | 2 | (13.3%) |
| PR | 3 | (20.0%) |
| Progressive disease | 10 | (66.7%) |
| CAR T product administered | ||
| Tisa-cel | 3 | (20.0%) |
| Axi-cel | 12 | (80.0%) |
| . | TL-pre-CAR-T set . | |
|---|---|---|
| N = 15 . | ||
| Age (y) | ||
| Median (min; max) | 71.0 (47; 80) | |
| Age ≥65 y | 10 | (66.7%) |
| Sex, male | 10 | (66.7%) |
| ECOG | ||
| 0-1 | 13 | (86.7%) |
| >2 | 2 | (13.3%) |
| LDH > normal | ||
| No | 7 | (50.0%) |
| Yes | 7 | (50.0%) |
| Missing | 1 | |
| Ann Arbor stage | ||
| I-II | 2 | (15.4%) |
| III-IV | 11 | (84.6%) |
| Missing | 2 | |
| aaIPI | ||
| 1 | 7 | (58.3%) |
| 2 | 4 | (33.3%) |
| 3 | 1 | (8.3%) |
| Missing | 3 | |
| Histology | ||
| LBCL | 11 | (73.3%) |
| Transformed FL | 3 | (20.0%) |
| Transformed Hodgkin | 1 | (6.7%) |
| HCT-CI-comorbidity evaluated | 15 | (100.0%) |
| At least 1 HCT-CI-comorbidity | 7 | (46.7%) |
| Nb of PLT before CAR-T∗ | ||
| Median (min; max) | 3.0 (2; 7) | |
| Prior autologous transplant | 1 | (6.7%) |
| Time from the initial diagnosis to CAR T-cell eligibility (y) | ||
| Median (min; max) | 1.62 (0.5; 18.2) | |
| Disease status before leukapheresis | ||
| Refractory | 14 | (100.0%) |
| Missing | 1 | |
| Disease status before CAR T-cell infusion | ||
| CR | 2 | (13.3%) |
| PR | 3 | (20.0%) |
| Progressive disease | 10 | (66.7%) |
| CAR T product administered | ||
| Tisa-cel | 3 | (20.0%) |
| Axi-cel | 12 | (80.0%) |
Abbreviations are explained in Table 1.
Up to 10 treatment lines may be collected from the DESCAR-T registry.